SCHEMBL26811489

SCHEMBL26811489

CCc1c(Oc2cccc(C(=O)NC)c2)nc(NS(=O)(=O)c2cnn(C)c2)nc1-c1ccccc1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 5/20 0.38
▸ EGFR P00533 2/20 0.38
▸ KDR P35968 2/20 0.38
▸ F10 P00742 2/20 0.37
▸ ULK1 O75385 3/20 0.36
▸ POLB P06746 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ FGFR3 P22607 3/20 0.35
▸ CCR2 P41597 3/20 0.35
▸ NTRK1 P04629 1/20 0.34
▸ PDGFRB P09619 1/20 0.34
▸ KIT P10721 1/20 0.34
▸ FLT3 P36888 1/20 0.34
▸ PTK2 Q05397 1/20 0.34
▸ F2 P00734 1/20 0.34
▸ HTR1A P08908 1/20 0.34
▸ HTR7 P34969 1/20 0.34
▸ GPR119 Q8TDV5 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26811492 0.92 FGFR1 (0.38) FGFR1EGFRKDRHPGDSMN1; SMN2
SCHEMBL29566810 0.92 FGFR1 (0.40) FGFR1EGFRKDRF10ULK1
SCHEMBL24309919 0.92 FGFR1 (0.40) FGFR1EGFRKDRF10ULK1
SCHEMBL26811516 0.89 FGFR1 (0.36) FGFR1EGFRKDRF10ULK1
SCHEMBL26811501 0.87 HTR1A (0.39) FGFR1EGFRKDRHPGDSMN1; SMN2
SCHEMBL26811500 0.87 GPR119 (0.38) HTR1AHTR7GPR119
SCHEMBL26811495 0.87 PARP1 (0.34) FGFR1EGFRKDRFGFR3PTK2
SCHEMBL26811481 0.84 HTR2C (0.40) EGFRHPGDHTR1AHTR7ALDH1A1
SCHEMBL29566856 0.83 HTR1A (0.41) HPGDHTR1AHTR7MEN1KMT2A
SCHEMBL24310357 0.83 HTR1A (0.41) HPGDHTR1AHTR7MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B FGFR1 2391/4885EGFR 818/4885KDR 4439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback